Sutro Biopharma Inc [STRO] stock is trading at $4.18, up 27.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The STRO shares have gain 17.75% over the last week, with a monthly amount drifted -13.01%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on November 09, 2023, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $12. Previously, Oppenheimer started tracking the stock with Outperform rating on October 06, 2023, and set its price target to $10. On March 21, 2023, downgrade downgraded it’s rating to Equal Weight and revised its price target to $8 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $35 as its price target on June 18, 2021. Stifel started tracking with a Buy rating for this stock on December 03, 2020, and assigned it a price target of $25. In a note dated September 02, 2020, Jefferies initiated an Buy rating and provided a target price of $21 on this stock.
Sutro Biopharma Inc [STRO] stock has fluctuated between $2.01 and $6.11 over the past year. Currently, Wall Street analysts expect the stock to reach $21.5 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $4.18 at the most recent close of the market. An investor can expect a potential return of 414.35% based on the average STRO price forecast.
Analyzing the STRO fundamentals
Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 153.73M for the trailing twelve months, which represents a growth of 1217.44%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -3.73%, Pretax Profit Margin comes in at -3.5%, and Net Profit Margin reading is -3.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.05 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.66 points at the first support level, and at 3.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.46, and for the 2nd resistance point, it is at 4.75.
Ratios To Look Out For
For context, Sutro Biopharma Inc’s Current Ratio is 4.50. On the other hand, the Quick Ratio is 4.50, and the Cash Ratio is 1.11. Considering the valuation of this stock, the price to sales ratio is 1.66, the price to book ratio is 1.70.
Transactions by insiders
Recent insider trading involved Vasquez Nicki, CHIEF PORT. STRAT & ALNCE OFCR, that happened on Jan 29 ’24 when 12185.0 shares were sold. Chief Business Officer, Shtylla Brunilda completed a deal on Aug 28 ’23 to sell 15428.0 shares. Meanwhile, Chief Business Officer Shtylla Brunilda sold 11613.0 shares on Aug 25 ’23.
